Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

Inclusion Criteria: * Age \> 18 years * Stage IV or un-resectable stage III melanoma * Presence of BRAF V600E/K mutation and CDNKN2A loss and expression of Rb using immunohistochemistry in a recent metastatic sample (\< 6 months) * A previous exposure to BRAF inhibitor or combination of BRAF and MEK inhibitors therapy is allowed unless it has been stopped more than 3 months before study enrolment(This will defined the two strata of the trial) * No previous therapy by MEK inhibitor unless associated with BRAF inhibitors * No previous therapy with the AKT/PI3K pathway inhibitor * Patients should have a tumour available for repeated biopsies for pharmacodynamics evaluation * Life expectancy of \> 3 months * ECOG performance status \<2 * Signed informed consent * Patient with health insurance coverage * No patient under guardianship or curators Exclusion Criteria: * Inadequate hepatic function defined as serum bilirubin\>25 μmol/l, transaminases \> 3.0 times the upper limit of normal (ULN) or 5ULN in cases of liver metastases; * Inadequate bone marrow function defined as absolute neutrophil count\<1500/mcl, platelets\<150000/mcl and haemoglobin\<8g/dL * Inadequate renal function with serum creatinine\>2.0mg/dl) and /or creatinine clearance\< 60 ml/min * Untreated brain metastases : Patients with brain metastases will be eligible if they have completed treatment 1 months prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for …